Systemic Lupus Erythematosus (SLE)
Conditions
Keywords
hematological manifestations, Nepal, organ involvement, systemic lupus erythematosus
Brief summary
The goal of this observational study is to evaluate hematological abnormalities among patients with systemic lupus erythematosus (SLE) admitted to a tertiary care center in Nepal. The main question it aims to answer is: \- What are the types and frequencies of hematological abnormalities seen in hospitalized SLE patients in Nepal? The study retrospectively reviews medical records of SLE patients admitted between April 2018 and March 2023 to collect data on hematologic parameters, demographic profiles, clinical manifestations.
Interventions
None listed
Sponsors
Patan Academy of Health Sciences
Study design
Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* All the patient diagnosed with systemic lupus erythematosus based on 2019 European League of Associations for Rheumatology and American College of Rheumatology (2019 EULAR/ACR) criteria.
Exclusion criteria
* Underlying hematological diseases or conditions: Patients who had hematological disease (e.g. hemophilia, leukemia, lymphoma) or conditions that could independently affect hematological parameters. * Incomplete records
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of patients with hematological abnormalities | Baseline at the time of hospital admission. (Cross-sectional) | Anemia was defined as a Hb of less than 13 g/dL in males and less than 12 g/dL in females. Leukopenia was defined as a WBC of less than 4000 per cubic millimeter (cu.mm). Thrombocytopenia was defined as a platelet count of less than 100,000 per cubic millimeter. Lymphopenia and neutropenia were defined as absolute lymphocyte count less than 1500 per cu.mm and absolute neutrophil count less than 1800 per cu.mm. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of SLE patients with pericarditis | Through the study completion from 2019 January to 2023 December. | Proportion of patients exhibiting pericarditis based on physician-documented diagnosis following 2019 EULAR/ACR criteria. |
| Percentage of SLE patients with respiratory involvement | Through the study completion from 2019 January to 2023 December. | Proportion of patients exhibiting respiratory involvement based on physician-documented diagnosis following 2019 EULAR/ACR criteria. |
| Percentage of SLE patients with gastrointestinal involvement | Through the study completion from 2019 January to 2023 December. | Proportion of patients exhibiting gastrointestinal involvement based on physician-documented diagnosis following 2019 EULAR/ACR criteria. |
| Percentage of SLE patients with mucocutaneous involvement | Through study completion from 2019 January to 2023 December. | Proportion of patients exhibiting at least one mucocutaneous manifestation (malar rash, discoid rash, alopecia, or oral ulcers) based on physician-documented diagnosis following 2019 EULAR/ACR criteria. |
| Percentage of SLE patients with musculoskeletal involvement | Through the study completion from 2019 January to 2023 December. | Proportion of patients exhibiting musculoskeletal involvement based on physician-documented diagnosis following 2019 EULAR/ACR criteria. |
| Percentage of SLE patients with neurological involvement | Through the study completion from 2019 January to 2023 December. | Proportion of patients exhibiting neurological involvement based on physician-documented diagnosis following 2019 EULAR/ACR criteria. |
| Percentage of SLE patients with kidney involvement | Through the study completion from 2019 January to 2023 December. | Proportion of patients exhibiting kidney involvement based on physician-documented diagnosis following 2019 EULAR/ACR criteria. |
Countries
Nepal
Outcome results
None listed